Stocks expected to have increasing option volume: MSTR IOVA CHRS CYTK
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'
December 27, 2023 1:43 PM ESTTruist Securities analyst Srikripa Devarakonda raised the price target on Cytokinetics (NASDAQ: CYTK) to $86.00 (from $60.00) while maintaining a Buy rating.
The analyst comments "Following mgmt conference call on Ph3 SEQUOIA-HCM data and speaking with mgmt postconference call, our conviction around best-in-class potential for... More
Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'
December 27, 2023 1:42 PM ESTOppenheimer analyst Justin Kim raised the price target on Cytokinetics (NASDAQ: CYTK) to $107.00 (from $54.00) while maintaining a Outperform rating.
The analyst comments "Aficamten appears on course toward a best-in-class trajectory in the treatment of oHCM following Phase 3 SEQUOIA results. With the call offering... More
